HIV Envelope Protein gp120 clinical trials

Who runs them

Industry 0 · Other 23

National Institute of Allergy and Infectious Diseases (NIAID) (23)

Often tested with

Tested in the same studies.

AIDS Vaccines (6) · Saponin QA-21V1 (2) · rgp120/HIV-1IIIB (2) · MF59 (1) · Aidsvax (1)

Studies

Open first, then newest update. How each study uses HIV Envelope Protein gp120 is read from its arms, and is right about nine times in ten.

Testing it · 23

• A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.CompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00001044Written as rgp120/HIV-1MN
• A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy AdultsCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00001031Written as rgp120/HIV-1MN
• A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine SchedulesCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00001076Written as rgp120/HIV-1 SF-2
• A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected MothersCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000774Written as rgp120/HIV-1MN
• A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00001096Written as rgp120/HIV-1MN
• A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult VolunteersCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00001072Written as rgp120/HIV-1 SF-2
• A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox-gp160 MN (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 Uninfected Adult VolunteersCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000813Written as rgp120/HIV-1 SF-2
• A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult VolunteersCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00001055Written as rgp120/HIV-1 SF-2
• A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected IndividualsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00001042Written as rgp120/HIV-1 SF-2
• A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult VolunteersCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000832Written as rgp120/HIV-1 SF-2
• A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3CompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000779Written as rgp120/HIV-1MN
• A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult VolunteersCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00000871Written as rgp120/HIV-1 SF-2
• A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000853Written as rgp120/HIV-1MN
• A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult VolunteersCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000847Written as rgp120/HIV-1 SF-2
• A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV InfectionCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000762Written as rgp120/HIV-1MN
• Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)CompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00001041Written as rgp120/HIV-1MN
• Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)WithdrawnPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00001046Written as rgp120/HIV-1 SF-2
• A Study to Test the Safety of Three Experimental HIV VaccinesCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000946Written as rgp120/HIV-1 SF-2
• A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative VolunteersCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000868Written as rgp120/HIV-1MN
• A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200 Mcg of gp120 (CHO) BIOCINE in MF59 Emulsion Versus the Emulsion Control: Three Injections at 0, 1, and 6 MonthsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000749Written as rgp120/HIV-1 SF-2

See all 23 studies that test HIV Envelope Protein gp120 →